200 related articles for article (PubMed ID: 31131695)
1. A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert!
Juhlin CC
Scand J Surg; 2020 Sep; 109(3):187-192. PubMed ID: 31131695
[TBL] [Abstract][Full Text] [Related]
2. TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up.
Stenman A; Hysek M; Jatta K; Bränström R; Darai-Ramqvist E; Paulsson JO; Wang N; Larsson C; Zedenius J; Juhlin CC
Endocr Pathol; 2019 Sep; 30(3):246-248. PubMed ID: 31154561
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter mutational screening as a tool to predict malignant behaviour in follicular thyroid tumours-three examples from the clinical routine.
Hysek M; Paulsson JO; Wang N; Jatta K; Lindh C; Fuentes-Martinez N; Shabo I; Zedenius J; Juhlin CC
Virchows Arch; 2018 Nov; 473(5):639-643. PubMed ID: 29860621
[TBL] [Abstract][Full Text] [Related]
4. Mutation profiles of follicular thyroid tumors by targeted sequencing.
Duan H; Liu X; Ren X; Zhang H; Wu H; Liang Z
Diagn Pathol; 2019 May; 14(1):39. PubMed ID: 31077238
[TBL] [Abstract][Full Text] [Related]
5. Clear Cell Variant of a Follicular Thyroid Tumor With Uncertain Malignant Potential: A Case Report.
Juhlin CC; Bränström R; Shabo I; Höög A
Int J Surg Pathol; 2019 May; 27(3):290-293. PubMed ID: 30370813
[TBL] [Abstract][Full Text] [Related]
6. 5hmC Immunohistochemistry: A Predictor of
Hysek M; Hellgren SL; Condello V; Xu Y; Larsson C; Zedenius J; Juhlin CC
J Histochem Cytochem; 2023 Aug; 71(8):451-458. PubMed ID: 37486076
[TBL] [Abstract][Full Text] [Related]
7. Follicular Thyroid Neoplasms: Comparison of Clinicopathologic and Molecular Features of Atypical Adenomas and Follicular Thyroid Carcinomas.
Cracolici V; Ritterhouse LL; Segal JP; Puranik R; Wanjari P; Kadri S; Parilla M; Cipriani NA
Am J Surg Pathol; 2020 Jul; 44(7):881-892. PubMed ID: 32282345
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
[TBL] [Abstract][Full Text] [Related]
9. Clinical application of human telomerase reverse transcriptase gene expression in thyroid follicular tumors by fine-needle aspirations using in situ hybridization.
Kammori M; Nakamura K; Hashimoto M; Ogawa T; Kaminishi M; Takubo K
Int J Oncol; 2003 May; 22(5):985-91. PubMed ID: 12684663
[TBL] [Abstract][Full Text] [Related]
10. BRAF and TERT promoter mutations: clinical application in thyroid cancer.
Chung JH
Endocr J; 2020 Jun; 67(6):577-584. PubMed ID: 32321884
[TBL] [Abstract][Full Text] [Related]
11. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
12. Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms.
Liou MJ; Chan EC; Lin JD; Liu FH; Chao TC
Cancer Lett; 2003 Mar; 191(2):223-7. PubMed ID: 12618337
[TBL] [Abstract][Full Text] [Related]
13. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
[TBL] [Abstract][Full Text] [Related]
14. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
Melo M; da Rocha AG; Vinagre J; Batista R; Peixoto J; Tavares C; Celestino R; Almeida A; Salgado C; Eloy C; Castro P; Prazeres H; Lima J; Amaro T; Lobo C; Martins MJ; Moura M; Cavaco B; Leite V; Cameselle-Teijeiro JM; Carrilho F; Carvalheiro M; Máximo V; Sobrinho-Simões M; Soares P
J Clin Endocrinol Metab; 2014 May; 99(5):E754-65. PubMed ID: 24476079
[TBL] [Abstract][Full Text] [Related]
15. Low frequency of TERT promoter mutations in a series of well-differentiated follicular-patterned thyroid neoplasms.
Proietti A; Sartori C; Macerola E; Borrelli N; Materazzi G; Vitti P; Basolo F
Virchows Arch; 2017 Dec; 471(6):769-773. PubMed ID: 28975450
[TBL] [Abstract][Full Text] [Related]
16. TERT Promoter Mutated Follicular Thyroid Carcinomas Exhibit a Distinct microRNA Expressional Profile with Potential Implications for Tumor Progression.
Paulsson JO; Zedenius J; Juhlin CC
Endocr Pathol; 2021 Dec; 32(4):513-516. PubMed ID: 34676499
[No Abstract] [Full Text] [Related]
17. Spatial Distribution Patterns of Clinically Relevant TERT Promoter Mutations in Follicular Thyroid Tumors of Uncertain Malignant Potential: Advantages of the Digital Droplet PCR Technique.
Hysek M; Jatta K; Hellgren LS; Stenman A; Larsson C; Zedenius J; Juhlin CC
J Mol Diagn; 2021 Feb; 23(2):212-222. PubMed ID: 33197629
[TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
[TBL] [Abstract][Full Text] [Related]
19. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
[TBL] [Abstract][Full Text] [Related]
20.
Paulsson JO; Mu N; Shabo I; Wang N; Zedenius J; Larsson C; Juhlin CC
Endocr Relat Cancer; 2018 Jul; 25(7):723-733. PubMed ID: 29692346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
